Coastal Infusion Administers Fabrazyme®

Fabrazyme ((agalsidase beta) is as an enzyme replacement therapy which is used for the treatment of Fabry disease. Fabry disease is a rare genetic disorder that is caused by a deficiency of the alpha-galactosidase, an enzyme that leads to the accumulation of a fatty substance called globotriaosylceramide (Gb3) in various tissues and organs.

Fabrazyme is an enzyme replacement therapy. Fabrazyme is designed to replace the human enzyme alpha-galactosidase A, which is lacking in patients with Fabry disease.

TThe active substance in Fabrazyme, agalsidase beta, is a copy of the human enzyme, produced by a method known as ‘recombinant DNA technology’ , in other words it is made by a cell that has received a gene (DNA), which makes it able to produce the enzyme. The replacement enzyme alpha-galactosidase A , helps to break down GL-3 and stops it from accumulating in the patient’s cells.

What It Treats

Eleprase is used to treat Fabry Disease.

Prescribed By

Fabrazyme is most often prescribed by Geneticists, Nephrologists, and Cardiologists.

How it’s Administered

Fabrazyme is administered by intravenous infusion. Fabrazyme about 90 minutes.

Frequency

Fabrazyme is generally administered every two weeks.

Related Drugs

Elfabrio

Additional Resources

• Fabrazyme Website 
• Prescribing Information
• Co-Pay Assistance

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies